The costs of compliance

Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry

Volumn 35, Issue 2, 2007, Pages 179-187

  Leeman, Eve ^a,b  

^a College of Physicians and Surgeon ^*  (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DOCTOR PATIENT RELATION; MEDICAL PRACTICE; MENTAL DISEASE; PATIENT COMPLIANCE; PRESCRIPTION; PSYCHOTHERAPY;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; COOPERATIVE BEHAVIOR; COST OF ILLNESS; DEPRESSIVE DISORDER; DRUG AND NARCOTIC CONTROL; DRUG COSTS; DRUG INDUSTRY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HUMANS; LEGISLATION, DRUG; MARKETING; MENTAL DISORDERS; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; PRESCRIPTIONS, DRUG; PSYCHIATRY; PSYCHOTROPIC DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34547423929     PISSN: 15460371     EISSN: None     Source Type: Journal    
DOI: 10.1521/jaap.2007.35.2.179     Document Type: Conference Paper

References (22)

1. Angell, M. (2005). The truth about the drug companies: How they deceive us and what to do about it. New York: Random House Trade Publications.
2. Ayd, F. (1961). Recognizing the depressed patient. New York: Grune & Stratton, Inc.
3. Blackwell, B. (1976). Treatment Adherence. British Journal of Psychiatry, 129, 513-531.
4. Blackwell, B. (1997). Treatment compliance and the therapeutic alliance. Milwaukee: Harwood Academic Publishers.
5. DiMatteo, M.R., & DiNicola, D. (1982). Achieving patient compliance: The psychology of the medical practitioner's role. New York: Pergamon Press.
6. Guess, H.A., Kleinman, A., Kusek, J.W., & Engel, L. (2002). The science of the placebo. London: BMJ Books.
7. Healy, D. (1997). The antidepressant era. Cambridge: Harvard University Press.
8. Healy, D. ( 2002). The creation of psychopharmacology. Cambridge: Harvard University Press.
9. Herrington, A. (1997). The placebo effect: An interdisciplinary exploration. Cambridge: Harvard University Press.
10. Jackson, S. (1986). Melancholia and depression from hippocratic times to modern times. New Haven: Yale University Press.
11. Kirsch, I., & Moore, T.J. (2002). The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. FDA. Prevention and Treatment, 5(1).
12. Kleinman, A. (1988a). The illness narratives. New York: Macmillan, Inc.
13. Kleinman, A. (1988b). Rethinking psychiatry. New York: Macmillan, Inc.
14. Kuhn, T. (1996). The structure of scientific revolutions: 3rd edition. Chicago: University of Chicago Press.
15. Lasagna, L. (1989). Congress, the FDA, and new drug development: Before and after 1962. Perspectives in Biology and Medicine, 32, 322-343.
16. McEvoy, J.P. (2006). CME: Effectiveness of antipsychotic drugs: Clinical implications of CATIE. The Center for Healthcare Education/Pfizer.
17. Moerman, D. (2002). Meaning, medicine and the "placebo effect." New York: Cambridge University Press.
18. Pollack, A. (2006). Take your pills, all your pills. The New York Times. March 11, 2006, pp. Business 1 and 13.
19. Schildkraut, J.J. (1965). The catecholamine hypothesis of affective disorders: A review of supporting evidence. American Journal of Psychiatry, November, 529-522.
20. Shepard, M. (1993). The placebo: From specificity to the nonspecific and back. Psychological Medicine, 23, 569-578.
21. Shorter, E. (1997). A history of psychiatry from the era of the asylum to the age of Prozac. New York: John Wiley & Sons.
22. Shorter, E. (2005). A historical dictionary of psychiatry. Oxford: Oxford University Press.